Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904163 · ClinicalTrials.gov registry record
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 13
- Enrollment target
NCT00904163: Completed study, sponsored by Stanford University.
NCT00904163 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904163 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional characteristics of patients who survive to adulthood.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904163
The ClinicalTrials.gov registry entry for NCT00904163 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00904163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904163 about?
NCT00904163 is a clinical study titled "Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa". Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional c...
What is the current status of trial NCT00904163?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2009-04. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT00904163?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.